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INTRODUCTION 
Diverticular disease (DD) 
is the fifth most important 
gastrointestinal disease in terms 
of healthcare costs in Western 
countries, with the highest 
rates in the United States and 
Europe. All age groups can be 
affected but prevalence increases 
with age, and cases in younger 
individuals are more likely to be 
complicated [1-3]. Diverticular 
diseases is a term used to include 
diverticulosis and diverticulitis 
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ABSTRACT
Background & Aims: Diverticular disease is a common gastrointestinal condition. Low-grade inflammation 
and altered intestinal microbiota have been identified as factors contributing to abdominal symptoms. 
Probiotics may lead to symptoms improvement by modifying the gut microbiota and are promising treatments 
for diverticular disease. The  aim of this study was to systematically review the efficacy of probiotics in 
diverticular disease in terms of remission of abdominal symptoms and prevention of acute diverticulitis.
Methods: According to PRISMA, we identified studies on diverticular disease patients treated with probiotics 
(Pubmed, Embase, Cochrane). The quality of these studies was evaluated by the Jadad scale. Main outcomes 
measures were remission of abdominal symptoms and prevention of acute diverticulitis. 
Results: 11 studies (2 double-blind randomized placebo-controlled, 5 open randomized, 4 non-randomized 
open studies) were eligible. Overall, diverticular disease patients were 764 (55.1% females, age 58-75 years). 
Three studies included patients with symptomatic uncomplicated diverticular disease, 4 studies with 
symptomatic uncomplicated diverticular disease in remission, 4 studies with complicated or acute diverticulitis. 
Mainly (72.7%) single probiotic strains had been used, most frequently Lactobacilli. Follow-up ranged from 1 
to 24 months. Interventions were variable: in 8 studies the probiotic was administered together with antibiotic 
or anti-inflammatory agents and compared with the efficacy of the drug alone; in 3 studies the probiotic 
was compared with a high-fibre diet or used together with phytoextracts. As an outcome measure, 4 studies 
evaluated the occurrence rate of acute diverticulitis, 6 studies the reduction of abdominal symptoms, and 6 
studies the recurrence of abdominal symptoms. Meta-analysis on the efficacy of probiotics in diverticular 
disease could not be performed due to the poor quality of retrieved studies. 
Conclusion: This systematic review showed that high-quality data on the efficacy of probiotics in diverticular 
disease are scant: the available data do not permit conclusions. Further investigation is required to understand 
how probiotics can be employed in this condition.
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and it may denote a clinically significant and symptomatic 
condition or asymptomatic diverticulosis. 
In the vast majority of individuals, colonic diverticula 
remain symptomless (diverticulosis), while approximately 20% 
of them develop symptoms, including recurrent abdominal 
pain or discomfort, bloating, changing in bowel habits 
(symptomatic diverticular disease). Only about 4% of patients 
develop acute diverticulitis, contradicting the common belief 
that diverticulosis has a high rate of progression [4, 5]. 
A significant proportion of patients with DD complain of 
symptoms resembling or overlapping those of irritable bowel 
syndrome (IBS), making a clear differentiation between the two 
conditions challenging [6-8]. It has been reported that, beyond 
abdominal symptoms, symptomatic DD is associated with a 
reduced quality of life, in particular vitality and emotional 
80 Lahner et al
J Gastrointestin Liver Dis, March 2016 Vol. 25 No 1: 79-86
health [9, 10], suggesting that DD may be experienced as a 
chronic illness marked by ongoing abdominal symptoms and 
psychosocial distress [11, 12]. A recent report showed that 
patients with acute diverticulitis may be at risk for subsequent 
development of IBS, a condition for which the term post-
diverticulitis IBS has been proposed [11], analogously to post-
infectious IBS proposed some years ago [13]. Both conditions, 
DD and IBS, presumably share some pathophysiological factors 
leading to symptom generation as low-grade inflammation, 
visceral hypersensitivity, abnormal colonic motility, and altered 
intestinal microbiota [14-19]. Changes in peri-diverticular 
bacterial flora has been suggested as a potential key step in 
the pathogenesis of diverticular inflammation and abdominal 
symptoms in DD [15], thus making probiotics an appealing 
therapy for this condition [20, 21]. 
Probiotics may modify the gut microbial balance leading 
to health benefits due to their anti-inflammatory effects and 
capability to enhance anti-infection defences by maintaining 
an adequate bacterial colonization in the gastrointestinal tract 
and by inhibiting colonic bacterial overgrowth and metabolism 
of pathogens [22-24]. A recent systematic review and meta-
analysis concluded that probiotics were effective treatments 
for IBS, showing that the relative risk (RR) of IBS symptoms 
persisting with probiotics compared with placebo was 0.79 
(95% CI 0.70-0.89) [25]. 
A recent consensus report stated with a 97% level of 
agreement, that to date there is insufficient evidence that 
probiotics are effective in reducing symptoms of diverticular 
disease [26]. Previous reviews on the use of probiotics in DD 
suggested that probiotics seem to be potentially useful in the 
management of this condition [20, 27]. In the last years, some 
new literature data on the role of probiotics in the management 
of diverticular disease have emerged. Based on this background, 
this study aimed to systematically review the efficacy of probiotic 
treatment in diverticular disease in terms of remission of 
abdominal symptoms and prevention of acute diverticulitis.
METHODS
Study selection
The search was conducted according to the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines [28]. The electronic databases PubMed 
MEDLINE (U.S. National Library of Medicine, Bethesda, 
MD), EMBASE Elsevier, and Cochrane Central Register of 
Controlled Trials were systematically searched according to 
the following search strategy: 
To assess all articles on colonic diverticulosis and 
diverticular disease of the colon: Explore colonic disease with 
an additional search using the key words: [(diverticulosis OR 
diverticular OR diverticula OR diverticulitis) AND (colon OR 
colonic OR sigmoid)] OR “diverticulosis, colonic” (MeSH). 
Combine with: probiotic OR probiotics OR synbiotic OR 
synbiotics OR symbiotic OR symbiotics or prebiotic OR 
prebiotics. Combine with: lactobacillus OR lactobacilli OR 
bifidobacteria OR escherichia OR saccharomyces OR casei 
OR paracasei OR boulardii OR rhamnosus OR helveticus 
OR acidophilus. Filter: NOT [Animal(MeSH)] NOT 
(Human(MeSH)) AND Animal(MeSH).
The search strategy excluded reviews, meta-analyses, case 
reports, and animal studies. The following study types were 
included: randomized clinical trials (blinded and/or placebo-
controlled), open randomized clinical trials, non-randomized 
open studies. Pediatric subjects were excluded from this 
review. No publication date restrictions were imposed. Reports 
published in English, German, French, Italian, and Spanish 
language were considered. 
Clinical studies published up to December 2015 were 
considered for inclusion if they described in adults (>18 
years) with DD the efficacy of probiotic treatment with respect 
to baseline (i) on improvement or remission of abdominal 
symptoms, and/or (ii) on prevention of acute diverticulitis. 
Potentially relevant articles were screened for eligibility 
independently in an un-blinded standardized manner by the 
two reviewers (E.L., B.A.), initially by abstract and then by 
full text when necessary to determine whether they met the 
inclusion criteria. In detail, reviews, letters and/or editorials 
were excluded on the basis of the abstract and/or title; in other 
cases the judgement of inclusion/exclusion was based on the 
evaluation of the full-text. Disagreement between reviewers 
was resolved by discussion. The reference lists of the identified 
articles as well as of identified relevant reviews were manually 
searched for additional studies that may have been overlooked 
using computer-assisted search strategy.   
Data extraction
We developed a data extraction sheet, pilot-tested it on three 
randomly-selected included studies, and refined it accordingly. 
One review author (E.L.) extracted the data from included 
studies and the second author (B.A.) checked the extracted 
data. Disagreements were resolved by discussion between the 
two review authors. The following information was extracted 
from each included paper: 1) author and year of publication; 
2) characteristics of probiotic strains (single/multiple, type); 
3) characteristics of study participants (number, mean age 
and gender); 4) type of diverticular disease; 5) study type 
and treatment arms; 6) type of intervention; 7) follow-up; 8) 
outcome data (remission of abdominal symptoms; occurrence 
of acute diverticulitis) / efficacy of intervention; 9) adverse 
effects of probiotics arms; 11) single or multiple centre. 
Statistical analysis
Originally, a meta-analysis was planned in order to provide 
a numerical estimate of the overall effect of interest taking into 
consideration as outcome measure (effect size) the proportion 
of patients who showed a positive response to probiotics 
treatment with respect to baseline or with respect to controls 
defined as the complete regression or the absence of recurrence 
of abdominal symptoms. Due the heterogeneity of the retrieved 
studies, meta-analysis was not considered applicable. The 
efficacy of the interventions reported in the retrieved studies 
was described in a qualitative manner. 
Quality assessment
The two reviewers evaluated the quality of all included studies 
using the Jadad scale for randomized controlled trials [29]. 
This scale awards a maximum of five points to each study. The 
considered categories are randomization, blinding of outcome 
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assessment, description of withdrawals and dropouts, description 
and appropriateness of randomization and blinding. A study can be 
awarded a maximum of one point for each category. Discrepancy 
in quality assessment was discussed and resolved by two reviewers.
RESULTS
Search results
The electronic search strategy identified a total of 192 
records from electronic databases, 171 of which were unique 
(Fig. 1). These articles were screened on the basis of title and 
abstract and, after application of the inclusion and exclusion 
criteria, 13 articles were retrieved for full-paper evaluation. 
Of these 13 full-papers, 11 met the eligibility criteria and 
were subjected to data extraction [30-40]. Two studies were 
excluded because in one the outcome (expression of TNF-alpha 
in segmental colitis associated with diverticulosis) [41] and in 
the other the intervention (oral polybacterial lysate suspension) 
was not pertinent to the present study purpose [42]. Manual 
searching of reference lists of potentially relevant papers and 
reviews did not add any more articles. Thus, 11 articles were 
included for qualitative synthesis. 
Quality assessment 
Details of the quality assessment of included studies 
are given in Supplementary Table S1 (see Supplementary 
material). Of the eleven included studies, four (36.4%) [30-
32, 36] achieved 1 point, five (45.4%) [33-35, 37, 38] achieved 
3 points, and two (18.2%) studies [39, 40] achieved 5 points 
according to Jadad scale.
Characteristics of included studies 
The main characteristics of the 11 included studies are 
summarized in Table I. These studies were performed over a 
period of 20 years, from 1993 to 2013, and five of them were 
more recent than 2010 [36-40]. Six studies [30-32, 34, 35, 39] 
were single and five [33, 36-38, 40] were multicenter studies. 
The 11 included studies investigated an overall total number 
of 764 patients with DD. Female gender was slightly prevalent 
(n=421, 55.1%). Patients had a mean age over 55 years in all 
studies, ranging from 58 to 75 years. In particular, five studies 
investigated patients with a mean age >65 years [30, 33, 35, 
37, 38].
Nine of the eleven studies were conducted in Europe, eight 
in Italy [30, 32-35, 3, 38, 40] and one in the Czech Republic [31]. 
From the remaining two studies, one was an Italian-Japanese 
collaboration [36] and one was performed in the USA [39].
With regard to the type of DD, three studies included 
patients with symptomatic uncomplicated DD [31, 37, 38] 
and four studies patients with symptomatic uncomplicated 
DD in remission [33, 35, 36. 40]. The remaining four studies 
investigated patients with complicated or acute diverticulitis 
[30, 32, 34, 39]. 
With regard to study type, two studies were double-blind 
randomized placebo-controlled trials [39, 40], five studies were 
open randomized trials [33- 35, 37, 38], the remaining were 
non-randomized open studies [30-32, 36].
Type of intervention, follow-up and outcome measure
With regard to the probiotics strains, in the majority of 
studies (72.7%), patients were treated with a single probiotic 
strain [30, 31, 33, 35, 37-40], and in only three studies multiple 
probiotic strains were employed [32, 34, 36]. Table II shows the 
strains of probiotics and their eventual prebiotic component 
used in the included studies. The most frequently investigated 
probiotic strains were different strains of Lactobacilli, while 
Bifidobacteria or other probiotic strains as Streptococcus or 
Escherichia were used less frequently. In three studies [36-
Fig. 1. Flow-chart of study selection.
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38] symbiotics were used, as probiotics were combined with 
prebiotics, and from one study [30] this information could 
not be extracted.
With regard to the follow-up protocol, the studies were 
very variable, and the follow-up periods ranged from 1 to 24 
months. Two studies observed patients for less than 6 months 
[31, 32], three studies followed patients for 6 months [36-38], 
five studies followed patients for 12 months [30, 33, 34, 39, 40] 
and one study observed patients for 24 months [35].
In addition, the interventions were variable between 
studies. In eight studies, the probiotic was administered 
together with a drug (antibiotic [rifaximin], anti-inflammatory 
agent as mesalamine or beclomethasone) [30-35, 39, 40] and 
compared with the efficacy of the drug alone. In five studies, 
however, there was a probiotic treatment arm without any 
associated drug [33, 36-38, 40], in three of them the probiotic 
arm was a control arm [33, 35, 40], in the remaining three 
studies, the probiotic was compared with a high-fibre diet [37, 
38] or used together with phytoextracts [36]. With regard to 
the outcome measures, four studies evaluated the occurrence 
rate of acute diverticulitis [30, 33, 36, 40], six studies assessed 
the reduction of abdominal symptoms [30, 31, 34, 37, 38, 39] 
and six studies assessed the remission of abdominal symptoms 
[31, 32, 33, 35, 36, 40]. Table III summarizes the type of 
interventions, follow-up protocols and outcome measures of 
the selected studies. Due to the poor quality of studies and 
the heterogeneity of study design, a meta-analysis could not 
be performed to provide a pooled estimate of the outcome 
measure. Details on the efficacy of probiotics treatment in the 
eleven included studies are reported in Table III. 
Table I. Main characteristics of the 11 selected studies on probiotics treatment in diverticular disease
Author Year (Ref) # Patients / F  / mean age 
(years)
Type of diverticular disease Study type / Arms Single center 
yes/no
Giaccari S 1993 [30] 79 / 34 / 63 Complicated DD in remission Open / 1 Yes
Fric P 2003 [31] 15 / 10 / 75 Symptomatic uncomplicated DD Open / 2 Yes
Tursi A 2005 [32] 12 / 5 / 58 Acute diverticular colitis Open / 1 Yes
Tursi A 2006 [33] 85 / 54 / 67 Symptomatic uncomplicated DD 
in remission
Open RT / 3 No
Tursi A 2007 [34] 30 / 11 / 60 Uncomplicated acute 
diverticulitis 
Open RT / 2 Yes
Tursi A 2008 [35] 75 / 42 / 65 Symptomatic uncomplicated DD 
in remission
Open RT / 5 Yes
Lamiki P 2010 [36] 46 / 36 / 62 Symptomatic uncomplicated DD 
in remission
Open / 1 No
Annibale B 2011 [37] 50 / 32 / 65 Symptomatic uncomplicated DD Open RT / 3 No
Lahner E 2012 [38] 45 /  35 /65 Symptomatic uncomplicated DD Open RT / 2 No
Stollman N 2013 [39] 117 / 61 / 58 CT confirmed acute diverticulitis DB placebo-controlled RT / 3 Yes
Tursi A 2013 [40] 210 / 101 /  62 Symptomatic uncomplicated DD 
in remission
DB placebo-controlled RT / 4 No
DB: double blind; DD: diverticular disease; F: female; Ref.: reference; RT: randomized trial
Table II. Probiotic strains employed in the 11 selected studies
Author Year (Ref) Strain(s) Symbiotic yes/no
Giaccari S 1993 [30] Lactobacillus (specific strain not reported) Not reported
Fric P 2003 [31] Escherichia coli strain Nissle No
Tursi A 2005 [32]
Tursi A 2007 [34]
Streptococcus thermophilus DSM 24731, Bifidobacterium  
longum DSM 24736, Bifidobacterium  breve DSM 24732, 
Bifidobacterium  infantis DSM 24737 , Lactobacillus  
acidophilus DSM 24735, Lactobacillus plantarum DSM 24730, 
Lactobacillus paracasei DSM 24733, Lactobacillus delbrueckii 
subsp. bulgaricus DSM 24734
No
Tursi A 2006 [33]
Tursi A 2008 [35]
Tursi A 2013 [40]
Lactobacillus casei subsp. DG
No
Lamiki P 2010 [36] Lactobacillus  acidophilus, Lactobacillus helveticus, 
Bifidobacterium. subsp. 420
Yes: Not specified (phytoextracts)
Annibale B 2011 [37] Lactobacillus paracasei subsp. paracasei F19 Yes: Glucooligosaccharides
Lahner E 2012 [38] Lactobacillus paracasei B21060 Yes: Arabinogalactan-xylooligosaccharides
Stollman N 2013 [39] Bifidobacterium infantis 35624 No
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Table III. Intervention and follow-up protocol in the 11 selected studies on probiotics treatment in diverticular disease
Author Year (Ref) Interventions Follow-up Outcome measure Efficacy of Intervention
Giaccari S 1993 [30] T1: Rifaximin 400 mg bid for 7 days + 
lactobacillus (2 cps) 7 days every month 
for 12 months
12 months Reduction of abdominal 
symptoms 
Occurrence of acute 
diverticulitis
70/79 pts regression of symptoms, 
4/79 reduction of symptoms
0/79 diverticulitis
Fric P 2003 [31] T1: probiotic + dichlorchinolinol + 
active coal tablets 
T2: dichlorchinolinol + active coal 
tablets for 1 week
3-6 weeks Reduction of abdominal 
symptoms 
Length of remisssion
Significant reduction of abdominal 
symptoms in T1 (p<0.001)
Obtained remissions were shorter in T2 
compared to T1 (p<001)
Tursi A 2005 [32] T1: beclomethasone dipropionate 10 
mg/day for 4 weeks + probiotic for 2 
weeks, followed by  beclomethasone 
dipropionate 5 mg/day for 4 weeks + 
probiotic for 2 weeks
8 weeks Reduction of  abdominal 
symptoms
Significant reduction of symptoms score 
(p<0.001)
Tursi A 2006 [33] T1: mesalamine 1.6 g/day; T2: probiotic 
15 days/month; T3: mesalamine 1.6 /day 
+ probiotic 15 days/months
12 months Remission of abdominal 
symptoms
29/29 T3 pts symptom-free versus 23/27 T1 
pts and 23/29 T2 pts (p<0.05)
1/84  pts diverticulitis
Tursi A 2007 [34] T1: balsalazide 2.25 g/day + rifaximin 
800 mg/day 10 days, then balsalazide 
2.25 g 10 days/ months + probiotic 15 
days/month for 12 months 
T2: balsalazide 2.25 g/day + rifaximin 
800 mg/day 10 days, then probiotic 15 
days/ month for 12 months
12 months Remission of acute 
diverticulitis
Assessment of symptom 
scores
Same time in T1 andT2 (5 vs 4 days)1 T1 
pts  and 2 T2 pts relapse of uncomplicated 
diverticulitis
11/15 T1 pts and 8/15 T2 pts symptom-free 
(p<0.01) at the end of follow-up
Tursi A 2008 [35] T1: Probiotic 10 days/ month  + 
mesalamine 800mg/ daily
T2: Probiotic 10 days/month  + 
mesalamine 1600 mg/ daily 
T3: Mesalamine 800 mg 10 days/ month
T4: Mesalamine 1600 mg 10 days/
month
T5: Probiotic for 10 days a month
24 months Remission of abdominal 
symptoms
Symptom-free at 24 months:
15/16 T1 pts 
12/13 T2 pts 
11/13 T3 pts 
8/10 T4 pts 
20/23 T5 pts 
Probiotic vs non-probiotic arms p=0.56
Lamiki P 2010 [36] T1: Probiotic + prebiotic + 
phytoextracts 10 ml t.i.d.for 6 months
6 months Remission of abdominal 
symptoms
Occurrence of acute 
diverticulitis
Symptom-free at 6 months: 
31/46 pts 
0 pts diverticulitis
Annibale B 2011 
[37]
T1: Probiotic + prebiotic (2 sachets daily 
+ high-fibre diet for 14 day/months for 
6 months
T2: 4 sachets daily for 14 days/month + 
high-fibre diet for 6 months
T3: high-fibre diet alone for 6 months
6 months Reduction of abdominal 
pain and bloating intensity
Bloating VAS decreased significantly in T1 
and T2 (p<0.05)
Abdominal pain <24h decreased in T1 and 
T2 (p>0.05)
Lahner E 2012 (38) T1: Probiotic + prebiotic 1 sachet daily 
+ high-fibre diet for 6 months
T2: High-fibre diet for 6 months
6 months Reduction of abdominal 
symptoms
Significant decrease of abdominal pain 
<24h and >24 h in T1 and T2 (p<0.05);
Significant decrease of intensity of 
abdominal pain and bloating in both groups 
(p<0.05)
Stollman N 2013 
[39]
T1: Probiotic + mesalamine 2.4 g/day 
for 12 weeks
T2: mesalamine 2.4 g/day  for 12 weeks 
T3: placebo for 12 weeks 
The treatment phase was followed by 
a 9-month nontreatment observation 
period.
12 months Reduction of global 
symptom score (GSS) of 10 
abdominal symptoms
No statistical difference between treatment 
arms in GSS at week 12 
At 12 months GSS stabilized at lower values 
compared to baseline in all treatment arms, 
no difference between treatment arms
Tursi A 2013 [40] T1:Probiotic 1 sachet/ day  for 10 days/
month + mesalamine 1.6 g/ day
T2: Probiotic 1 sachet day for 10 days/ 
months + mesalamine placebo
T3: Probiotic placebo + mesalamine 1.6 
g/ day for 10 days/ month
T4: Probiotic placebo + mesalamine 
placebo
12 months Remission of abdominal 
symptoms
Recurrence of abdominal 
symptoms
Occurrence of acute 
diverticulitis
T1 13/54 (24.1%) 
T2 8/55 (14.5%) 
T3 5/51 (9.8%) 
T4 2/50 (4.0%) 
T1 vs T4 p<0.01) 
T1 0/54 (p<0.01 vs other arms) 
T2 8/55 (14.5%)  
T3 7/51 (13.7%) 
T4 23/50 (46.0%) 
6/50 T4 pts and 1/55 T2 pts, no cases in T1 
(n=54) and T3 (n=51) pts
T1 = treatment arm 1; T2 treatment arm 2; T3 treatment arm 3; T4 treatment arm 4; T5 treatment arm 5; pts = patients
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Adverse effects
Nine studies did not observe any adverse effects related to 
the probiotic treatment [30, 31, 33-38, 40]. In one study adverse 
effects were not reported [32] and in one study [39] a relatively 
high proportion of adverse effects was present in all treatment 
arms (probiotic 39%, mesalamine 47% and placebo 41%).
DISCUSSION
This systematic review represents an attempt to provide 
an updated measure of evidence on the efficacy of probiotics 
in DD, in terms of symptoms control and prevention of acute 
diverticulitis. To our knowledge this is the first systematic 
review to collect all available data on the use of probiotics in 
DD. Previous reviews on probiotics in DD were performed 
some years ago (2009 and 2010), but they did not perform a 
systematical search of the literature,  nor a meta-analysis and 
they included only four and seven studies, respectively. These 
suggested that probiotics seem to be potentially useful in the 
management of this condition [4, 27].
This systematic review was conducted applying the rigorous 
methodology according to PRISMA guidelines [28], the 
used search strategy was reported in full, and to enhance the 
yield of computer-based electronic database searching, the 
reference lists of relevant papers and reviews were manually 
searched. No date restriction was given and reports in English, 
German, French, Italian, and Spanish language were taken 
into consideration. 
However, several limitations, largely arising from the nature 
of the included studies available for qualitative synthesis, impair 
the results of this systematic review. The overall number of 
retrieved studies was relatively low, the quality of included 
studies was relatively poor, as only two of the included studies 
were double-blinded randomized controlled trials, and study 
designs were heterogeneous making a meta-analysis not 
applicable. Moreover, five of the eleven included trials had 
been performed by the same authors. The follow-up periods 
in the single studies were very variable. The probiotic strains 
employed as treatment were very different as were the treatment 
protocols with regard to timing, dosage or combination with 
other drugs. Specific strains of probiotics may have different 
effects in patients with DD, and pooling different studies using 
different strains may not be a suitable method to evaluate their 
efficacy. The limited number of included studies was too low to 
analyze single probiotic strains. Also the type of DD was not 
homogeneous between studies as some studies investigated 
patients with uncomplicated DD and other studies patients 
with acute diverticulitis in remission. Some studies evaluated 
the maintenance of remission of abdominal symptoms, 
while other studies investigated the reduction of abdominal 
symptoms. All these variables may potentially influence the 
clinical response to probiotic treatment.   
Data emerging from the qualitative synthesis of the 
retrieved studies clearly show that a meta-analysis on the 
efficacy of probiotics from these studies is not applicable 
to establish if probiotic treatment may be relevant in DD. 
However, with all the limits above described, the efficacy of 
probiotics in DD reported in the single controlled studies seem 
to show an apparent trend to a positive clinical response on 
abdominal symptoms or their recurrence, especially in patients 
with symptomatic uncomplicated DD [31- 34, 37-40] (Table 
III). One possible explanation of this apparent clinical effect in 
the single studies lies in the fact that a significant proportion 
of patients with DD complain of symptoms resembling or 
overlapping those of IBS [6-8]. This further increases the 
difficulty to evaluate a possible efficacy of probiotic treatment 
on abdominal symptoms in patients with DD since probiotics 
have been shown to be effective treatment for IBS compared 
with placebo in a recent systematic review and meta-analysis 
[25].
CONCLUSION
This systematic review showed that there remains still a 
paucity of evidence for the efficacy of probiotics in DD and 
high-quality data on efficacy of probiotics in DD are scant. 
Available data do not allow definite conclusions. Further 
investigation is required to understand how probiotics can be 
employed in this condition.
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Supplementary Table S1. Quality assessment according to Jadad scale* 
Author Year (Ref) Score 1) 2) 3) 4) 5) 6) 
Giaccari 1993 (30) 1/5 0 0 1 0 0 0 
Fric 2002 (31) 1/5 0 0 1 0 0 0 
Tursi 2005 (32) 1/5 0 0 1 0 0 0 
Tursi 2006 (33) 3/5 1 0 1 1 0 0 
Tursi 2007 (34) 3/5 1 0 1 1 0 0 
Tursi 2008 (35) 3/5 1 0 1 1 0 0 
Lamiki 2010 (36) 1/5 0 0 1 0 0 0 
Annibale 2011 (37) 3/5 1 0 1 1 0 0 
Lahner 2012 (38) 3/5 1 0 1 1 0 0 
Stollman 2013 (39) 5/5 1 1 1 1 1 0 
Tursi 2013 (40) 5/5 1 1 1 1 1 0 
Ref = reference; 
1=yes; 0=no;  
1) Was the study described as randomized? 
2) Was the outcome assessment described as blinded? 
3) Was there a description of withdrawals and dropouts? 
4) Was the method of randomization well-described and appropriate? 
5) Was the method of blinding of the assessment of outcomes well-described and appropriate? 
6) Deduction of 1 point if methods for randomization or blinding were inappropriate. 
* see Reference 29). 
 
